Payment overview · 2025
General Payments
$1,447.79
53 reported records · 13 companies
Healthcare provider profile · identity verified
Andrey Lev-Weissberg, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PARK RIDGE, IL · NPI 1245206655
Verified facts
What the public records show
CMS Open Payments records show Andrey Lev-Weissberg, MD received $1,447.79 in general payments during 2025 across 53 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Eliquis, Ingrezza, Linzess, Ozempic, Rexulti, Zubsolv.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
Orexo US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zubsolv as an associated drug or biological on 1867 records involving 794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Zubsolv by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 436 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $382.09 | 26.4% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $330.49 | 22.8% | 14 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $262.21 | 18.1% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $194.69 | 13.4% | 11 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $64.41 | 4.5% | 2 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $38.98 | 2.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.20 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.82 | 2.0% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $25.63 | 1.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.73 | 1.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.42 | 1.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.19 | 1.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.93 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,447.79 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $712.58 | 22 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $262.21 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $152.75 | 9 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $64.41 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $41.94 | 2 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $38.98 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.20 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.20 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.82 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $25.63 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 436 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Zubsolv zubsolv |
2025 | Zubsolv | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
| Orexo US, Inc. Exact reporting entity; no affiliate inference |
2025 | Zubsolv open payments reported associated product |
CMS Open Payments — General Payments 1867 supporting records · 794 recipient NPIs · example record 1190507283 |
Zubsolv · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
19 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
436 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 679 | 121 |
| Eliquis | Apixaban | 436 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 379 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 367 | 81 |
| Gabapentin | Gabapentin | 364 | 61 |
| Lisinopril | Lisinopril | 303 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 58 |
| Losartan Potassium | Losartan Potassium | 279 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 53 |
| Metformin Hcl | Metformin Hcl | 233 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 39 |
| Mirtazapine | Mirtazapine | 222 | 42 |
| Omeprazole | Omeprazole | 215 | 51 |
| Carvedilol | Carvedilol | 203 | 36 |
| Trazodone Hcl | Trazodone Hcl | 197 | 41 |
| Furosemide | Furosemide | 176 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 42 |
| Potassium Chloride | Potassium Chloride | 136 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 24 |
| Famotidine | Famotidine | 129 | 19 |
| Donepezil Hcl | Donepezil Hcl | 125 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 121 | 22 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 100 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 23 |
| Warfarin Sodium | Warfarin Sodium | 99 | 11 |
| Sevelamer Carbonate | Sevelamer Carbonate | 96 | suppressed |
| Memantine Hcl | Memantine Hcl | 94 | 15 |
| Levetiracetam | Levetiracetam | 93 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 17 |
| Montelukast Sodium | Montelukast Sodium | 89 | 18 |
| Doxepin Hcl | Doxepin Hcl | 85 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 23 |
| Divalproex Sodium | Divalproex Sodium | 82 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 11 |
| Sertraline Hcl | Sertraline Hcl | 78 | 18 |
| Allopurinol | Allopurinol | 77 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 18 |
| Xarelto | Rivaroxaban | 77 | suppressed |
| Clonazepam | Clonazepam | 76 | 16 |
| Midodrine Hcl | Midodrine Hcl | 73 | 22 |
| Olanzapine | Olanzapine | 72 | suppressed |
| Alprazolam | Alprazolam | 71 | 22 |
| Clonidine Hcl | Clonidine Hcl | 71 | suppressed |
| Jardiance | Empagliflozin | 71 | 11 |
| Ozempic | Semaglutide | 71 | 20 |
| Tramadol Hcl | Tramadol Hcl | 71 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 19 |
| Spironolactone | Spironolactone | 67 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 63 | 15 |
| Simvastatin | Simvastatin | 63 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 21 |
| Buspirone Hcl | Buspirone Hcl | 60 | 15 |
| Clozapine | Clozapine | 60 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 60 | suppressed |
| Bumetanide | Bumetanide | 59 | 12 |
| Linzess | Linaclotide | 58 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 30 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 56 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | suppressed |
| Topiramate | Topiramate | 54 | suppressed |
| Lamotrigine | Lamotrigine | 53 | suppressed |
| Ezetimibe | Ezetimibe | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 50 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 50 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 14 |
| Cephalexin | Cephalexin | 47 | 32 |
| Meloxicam | Meloxicam | 47 | 12 |
| Methylprednisolone | Methylprednisolone | 47 | 40 |
| Pregabalin | Pregabalin | 47 | suppressed |
| Glipizide | Glipizide | 45 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 11 |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 39 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Prednisone | Prednisone | 38 | 13 |
| Hydrocortisone | Hydrocortisone | 36 | suppressed |
| Lidocaine | Lidocaine | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 24 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Humalog | Insulin Lispro | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 26 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Buprenorphine | Buprenorphine | 24 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 24 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 22 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Nystatin | Nystatin | 21 | 14 |
| Sodium Chloride | 0.9 % Sodium Chloride | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Ingrezza | Valbenazine Tosylate | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 19 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 17 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 11 |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Caplyta | Lumateperone Tosylate | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,447.79 · 53 records | Otsuka America Pharmaceutical, Inc. | AUSTEDO XR, CAPLYTA, CREON, ELIQUIS, EVENITY, INGREZZA, JOURNAVX, LINZESS, MOUNJARO, Ozempic, REXULTI, Rybelsus, VRAYLAR, ZEPBOUND, Zubsolv | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error